UK company Optos, plc (LSE: OPTS) has announced its next generation imaging device, branded “Daytona”, at the Boston meeting of the American Academy of Optometry.… Read More »Optos, plc unveils next generation desktop imaging device at American Academy of Optometry meeting
VisionCare Ophthalmic Technologies, Inc., a specialty medical device company based in Saratoga California, have announced that the Centres for Medicare and Medicaid Services (CMS), a… Read More »VisionCare’s implantable telescope secures reimbursement
A new UK-based ophthalmology company – KalVista Pharmaceuticals – has announced the completion of an £8 million Series A funding round led by Novo A/S… Read More »A new ophthalmic company – KalVista Pharmaceuticals – raises £8M to fund DME therapies
iCo Therapeutics (TSX-V: ICO, Vancouver, Canada) has announced the execution of a licensing deal with Immune Pharmaceuticals (Ness-Ziona, Israel) for Bertilimumab (iCo-008) for systemic uses.… Read More »iCo Therapeutics enters license deal with Immune Pharmaceuticals
Pfizer, Inc (NYSE: PFE), New York, has notified the European Medicines Agency (EMA) of its decision to withdraw an application to extend the therapeutic indication… Read More »Pfizer withdraws application for an extension of the indication for Macugen
Regeneron Pharmaceuticals (NASDAQ:REGN), Tarrytown, New York, will undergo an FDA priority review of its VEGF Trap Eye (recently renamed “Eylea aflibercept”) on August 20th, the… Read More »Regeneron Pharmaceutical’s pricing strategy may be key to success
In a collaboration with the University of Birmingham, Quark Pharmaceuticals, a Californian based biotech company with research facilities at the Weismann Science Park in Israel,… Read More »Quark Pharmaceuticals Inc. and the University of Birmingham publishes data on anti-apoptotic result
Regeneron Pharmaceuticals & Bayer Healthcare have announced the submission of a marketing authorisation application (MAA) for VEGF Trap Eye for the treatment of neovascular age… Read More »Regeneron & Bayer file marketing authorisation application for VEGF Trap Eye
Lpath, Inc, a San Diego based therapeutic antibody company quoted on the US OTCBB (LPTN) has announced the initiation of enrolment for its anti-angiogenic antibody… Read More »Lpath Inc initiates Phase 1b/2a trial for iSONEP in retinal detachment and vasculopathy secondary to
Quark Pharmaceuticals, a Californian based RNAi specialised biotech company, has announced changes to a Pfizer collaborative research agreement following receipt of results from a randomized… Read More »Quark announces a revision to an siRNA Pfizer agreement on diabetic macular edema